British Columbia Cancer Agency

Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes. (2022) Meagher NS, Gorringe KL, Wakefield MJ, Bolithon A, Pang CNI, Chiu DS, Anglesio MS, et al. Journal article A Delphi study and International Consensus Recommendations: The use of bolus in the setting of postmastectomy radiation therapy for early breast cancer (2021) Kaidar-Person O, Dahn HM, Nichol AM, Boersma LJ, de Ruysscher D, Meattini I, Pignol JP, et al. Journal article INTERNATIONAL EXPERT DELPHI CONSENSUS GUIDELINES FOR THE USE OF BOLUS IN POST MASTECTOMY RADIATION THERAPY (2021) Dahn H, Boersma L, De Ruysscher D, Meattini I, Offersen B, Pignol JP, Aristei C, et al. Conference contribution THE USE OF BOLUS IN POSTMASTECTOMY RADIATION THERAPY FOR BREAST CANCER: A SYSTEMATIC REVIEW (2021) Dahn H, Boersma L, De Ruysscher D, Meattini I, Offersen B, Pignol JP, Belkacemi Y, et al. Journal article Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival (2021) Slamon DJ, Neven P, Chia S, Jerusalem G, De Laurentiis M, Im S, Petrakova K, et al. Journal article The use of bolus in postmastectomy radiation therapy for breast cancer: A systematic review (2021) Dahn HM, Boersma LJ, de Ruysscher D, Meattini I, Offersen BV, Pignol JP, Aristei C, et al. Journal article, Review article Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis (2021) Gelmon KA, Fasching P, Couch FJ, Balmaña J, Delaloge S, Labidi-Galy I, Bennett J, et al. Journal article Corrigendum to ‘Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival’: [Annals of Oncology Volume 32, Issue 8, August 2021, Pages 1015-1024] (Annals of Oncology (2021) 32(8) (1015–1024), (S0923753421015532), (10.1016/j.annonc.2021.05.353)) (2021) Slamon DJ, Neven P, Chia S, Jerusalem G, De Laurentiis M, Im S, Petrakova K, et al. Journal article, Erratum Patient-reported outcomes (PROs) in advanced breast cancer (ABC) treated with ribociclib (RIB) plus fulvestrant (FUL) as first-line (1L) and second-line (2L) therapy in MONALEESA-3 (ML-3) (2020) Fasching P, Neven P, Jerusalem G, Beck JT, Chan A, De Laurentiis M, Bianchi GV, et al. Conference contribution Meningioma 1 is indispensable for mixed lineage leukemia-rearranged acute myeloid leukemia (2020) Sharma A, Jyotsana N, Gabdoulline R, Heckl D, Kuchenbauer F, Slany R, Ganser A, Heuser M Journal article